{"id":"tak-385","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TAK-385 reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"TAK-385 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:18.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07025369","phase":"PHASE2","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-25","conditions":"Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT07182279","phase":"PHASE1, PHASE2","title":"Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-08-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":29},{"nctId":"NCT06330805","phase":"PHASE2","title":"Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-08-12","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT06463457","phase":"PHASE2","title":"Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atish Choudhury, MD","startDate":"2024-12-13","conditions":"Prostate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate Cancer","enrollment":33},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT06130995","phase":"PHASE1","title":"Relugolix + Enzalutamide Study in High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2024-12-26","conditions":"Androgen Deprivation Therapy, Locally Advanced Prostate Cancer","enrollment":46},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT07440043","phase":"","title":"Relugolix for Endometriosis Associated Pain","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2026-02-25","conditions":"Endometriosis, Endometriosis-related Pain, Pelvic Pain Syndrome","enrollment":33},{"nctId":"NCT06650579","phase":"PHASE3","title":"REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-31","conditions":"Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":72},{"nctId":"NCT07100782","phase":"PHASE3","title":"Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-12-08","conditions":"Endometriosis, Pelvic Pain","enrollment":130},{"nctId":"NCT06111313","phase":"PHASE2","title":"The University of Miami Adapt (UAdapt) Trial","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-11-06","conditions":"Prostate Cancer","enrollment":130},{"nctId":"NCT05320406","phase":"PHASE2","title":"RElugolix VErsus LeUprolide Cardiac Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-06-06","conditions":"Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8","enrollment":94},{"nctId":"NCT06631521","phase":"PHASE1","title":"Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer","status":"RECRUITING","sponsor":"AdventHealth","startDate":"2024-10-22","conditions":"Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery","enrollment":30},{"nctId":"NCT06671548","phase":"PHASE3","title":"Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-01-15","conditions":"Heavy Menstrual Bleeding, Uterine Fibroids","enrollment":120},{"nctId":"NCT06397703","phase":"PHASE2","title":"ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-04-16","conditions":"Prostate Cancer","enrollment":392},{"nctId":"NCT06111781","phase":"PHASE2","title":"The SUGAR Study; SBRT and Relugolix) for Prostate Cancer","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-04-15","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT06734130","phase":"PHASE2","title":"Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-01-10","conditions":"Metastatic Castration Sensitive Prostate Cancer","enrollment":25},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":"Prostate Adenocarcinoma","enrollment":2050},{"nctId":"NCT05053152","phase":"PHASE2","title":"Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-04-20","conditions":"Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma","enrollment":194},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":"Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":2753},{"nctId":"NCT07111247","phase":"PHASE4","title":"Insights in Endocervical Mucus Secretion","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-01-02","conditions":"Cervical Mucus","enrollment":15},{"nctId":"NCT04756037","phase":"PHASE3","title":"Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2021-03-18","conditions":"Contraception","enrollment":1020},{"nctId":"NCT07302451","phase":"PHASE2","title":"REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-12-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":50},{"nctId":"NCT06531499","phase":"PHASE1","title":"A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-11","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":106},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT05241860","phase":"PHASE2","title":"Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-11-21","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":79},{"nctId":"NCT06462014","phase":"","title":"Description of Relugolix Use in Patients With Prostate Cancer Within the VHA","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-06-19","conditions":"Prostate Cancer","enrollment":507},{"nctId":"NCT05189457","phase":"PHASE2","title":"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-01-25","conditions":"Prostate Cancer, Stage IV Prostate Cancer","enrollment":32},{"nctId":"NCT05628363","phase":"NA","title":"Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-18","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":28},{"nctId":"NCT07216248","phase":"PHASE2","title":"Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-10-27","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":160},{"nctId":"NCT06499870","phase":"PHASE2","title":"Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-09-06","conditions":"Prostate Adenocarcinoma","enrollment":50},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT05538689","phase":"PHASE4","title":"Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-11-20","conditions":"Metrorrhagia, Pelvic Pain, Menorrhagia","enrollment":""},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT06279195","phase":"PHASE2","title":"Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment","status":"WITHDRAWN","sponsor":"Endeavor Health","startDate":"2024-06-01","conditions":"Pelvic Pain","enrollment":""},{"nctId":"NCT07142967","phase":"NA","title":"Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-08-15","conditions":"Intraprostatic Prostate Cancer","enrollment":28},{"nctId":"NCT05739123","phase":"","title":"Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring","status":"RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2023-05-08","conditions":"Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk","enrollment":728},{"nctId":"NCT05605964","phase":"PHASE3","title":"Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2023-01-25","conditions":"Prostate Cancer","enrollment":387},{"nctId":"NCT04666129","phase":"PHASE1","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2021-02-18","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer","enrollment":48},{"nctId":"NCT06953076","phase":"","title":"Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-05-02","conditions":"Uterine Bleeding, Uterine Leiomyomas, Uterine Hemorrhage","enrollment":111},{"nctId":"NCT05467176","phase":"","title":"A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2022-10-04","conditions":"Prostate Cancer","enrollment":999},{"nctId":"NCT05765500","phase":"PHASE2","title":"RecoverPC: Relugolix vs GnRH Agonist in Quality of Life","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-12","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":110},{"nctId":"NCT05862272","phase":"PHASE3","title":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","status":"RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2023-08-14","conditions":"Uterine Fibroids, Endometriosis","enrollment":1000},{"nctId":"NCT05739136","phase":"","title":"MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2025-04-30","conditions":"Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk","enrollment":530},{"nctId":"NCT07069465","phase":"EARLY_PHASE1","title":"Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging","status":"COMPLETED","sponsor":"Urology Clinics of North Texas","startDate":"2024-06-15","conditions":"Prostate Cancer","enrollment":10},{"nctId":"NCT06439524","phase":"PHASE3","title":"The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Main Line Health","startDate":"2024-08-15","conditions":"Endometriosis","enrollment":110},{"nctId":"NCT04523207","phase":"PHASE2","title":"A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-08-19","conditions":"Prostatic Neoplasms","enrollment":108},{"nctId":"NCT05679388","phase":"PHASE1","title":"A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2023-02-13","conditions":"Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT03751124","phase":"PHASE3","title":"Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2018-10-16","conditions":"Uterine Leiomyoma, Uterine Fibroids","enrollment":229},{"nctId":"NCT03412890","phase":"PHASE3","title":"LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-10-19","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":477},{"nctId":"NCT06312761","phase":"PHASE1, PHASE2","title":"Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2024-06-01","conditions":"Hypogonadism, Male","enrollment":10},{"nctId":"NCT06129851","phase":"PHASE2","title":"Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2023-11-20","conditions":"Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8","enrollment":90},{"nctId":"NCT03654274","phase":"PHASE3","title":"SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2018-05-22","conditions":"Endometriosis","enrollment":802},{"nctId":"NCT03103087","phase":"PHASE3","title":"LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-06-14","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":382},{"nctId":"NCT03049735","phase":"PHASE3","title":"LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-26","conditions":"Heavy Menstrual Bleeding, Uterine Fibroid","enrollment":388},{"nctId":"NCT03085095","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-04-18","conditions":"Prostate Cancer","enrollment":1134},{"nctId":"NCT04714554","phase":"PHASE1","title":"A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2021-01-06","conditions":"Healthy","enrollment":43},{"nctId":"NCT04978688","phase":"PHASE1","title":"Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2016-06-16","conditions":"Healthy","enrollment":48},{"nctId":"NCT03204331","phase":"PHASE3","title":"SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-11-01","conditions":"Endometriosis Related Pain","enrollment":623},{"nctId":"NCT03204318","phase":"PHASE3","title":"SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain","status":"COMPLETED","sponsor":"Myovant Sciences GmbH","startDate":"2017-12-07","conditions":"Endometriosis Related Pain","enrollment":638},{"nctId":"NCT03931915","phase":"PHASE3","title":"Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis","status":"COMPLETED","sponsor":"ASKA Pharmaceutical Co., Ltd.","startDate":"2019-05-08","conditions":"Endometriosis","enrollment":335},{"nctId":"NCT02655237","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-05","conditions":"Uterine Fibroids","enrollment":281},{"nctId":"NCT02655224","phase":"PHASE3","title":"A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-03-26","conditions":"Uterine Fibroids","enrollment":65},{"nctId":"NCT02141659","phase":"PHASE1","title":"A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-05-01","conditions":"Hormone Treatment-naïve Participants With Prostate Cancer","enrollment":43},{"nctId":"NCT02083185","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2014-03-26","conditions":"Prostate Cancer","enrollment":136},{"nctId":"NCT02792062","phase":"PHASE1","title":"A Food Effect Study of TAK-385 Final Formulation","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-07-04","conditions":"Japanese Premenopausal Healthy Adult Women","enrollment":12},{"nctId":"NCT02135445","phase":"PHASE2","title":"Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Prostate Cancer","enrollment":103},{"nctId":"NCT02252354","phase":"PHASE1","title":"TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-09","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT02396147","phase":"PHASE1","title":"Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03","conditions":"Healthy Volunteers","enrollment":54},{"nctId":"NCT02093390","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2014-03","conditions":"Prostate Cancer, Endometriosis","enrollment":40},{"nctId":"NCT01452685","phase":"PHASE2","title":"A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-03","conditions":"Endometriosis","enrollment":397},{"nctId":"NCT01458301","phase":"PHASE2","title":"Efficacy and Safety of TAK-385 in the Treatment of Endometriosis","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Endometriosis","enrollment":487},{"nctId":"NCT01452659","phase":"PHASE2","title":"Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-10","conditions":"Uterine Fibroids","enrollment":216}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["relugolix"],"phase":"phase_3","status":"active","brandName":"TAK-385","genericName":"TAK-385","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-385 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}